Real‐world outcomes of adjuvant therapies in stage <scp>III</scp> / <scp>IV</scp> melanoma: Insights from the French <scp>RIC</scp> ‐ <scp>MEL</scp> cohort
M. Vuillemey(Centre Hospitalier Universitaire de Nantes), G. Quereux(Inserm), A. Khammari(Inserm), D. Legoupil(Laboratoire des Sciences et Techniques de l’Information de la Communication et de la Connaissance), Thomas Goronflot(Inserm), A. Dupuy(Université de Rennes), E. Hainaut(Centre Hospitalier Universitaire de Poitiers), Yannick Le Corre(Université Nantes Angers Le Mans), Julie Cassecuel(Centre Hospitalier Universitaire de Nantes), L. Misery(Centre Hospitalier Régional Universitaire de Brest), P. Celérier(Centre Hospitalier de La Rochelle)
Cited by 0
Related Papers
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
|Journal of Investigative Dermatology|2014|954
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748
Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis
|New England Journal of Medicine|2020|280
Definition of Sensitive Skin: An Expert Position Paper from the Special Interest Group on Sensitive Skin of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2016|228
Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis
|New England Journal of Medicine|2023|184